Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1843. Manual Lymph Drainage Combined With Compression Therapy for Arm Lymphedema Following Breast Cancer Treatment

Manual Lymph Drainage Combined With Compression Therapy for Arm Lymphedema Following Breast Cancer Treatment Manual Lymph Drainage Combined With Compression Therapy for Arm Lymphedema Following Breast Cancer Treatment We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Manual Lymph Drainage Combined With Compression Therapy for Arm Lymphedema Following (...) Breast Cancer Treatment Share: Reading time approx. 9 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Summary and Conclusions Technology and target group Arm lymphedema is a common complication following breast cancer treatment. The condition increases arm volume, causes a sensation of heaviness and tightness, and in some patients it may cause pain and impair mobility. Over time, the increase in fat volume results in tissue changes, making

Swedish Council on Technology Assessement2005

1844. Aromatase Inhibitors in Breast Cancer

Aromatase Inhibitors in Breast Cancer Aromatase Inhibitors in Breast Cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Aromatase Inhibitors in Breast Cancer Share: Reading time approx. 9 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Summary and Conclusions Technology and target group (...) Approximately 6 500 new cases of breast cancer are detected annually in Sweden. Early stages of the disease are treated surgically. Various types of adjuvant therapy may also be prescribed, e.g., hormonal agents. Despite adjuvant hormonal therapy, approximately 13 percent of the patients experience a relapse of breast cancer within 5 years. At recurrence a progress to advanced breast cancer, i.e., metastasis beyond the mammary gland and regional lymph nodes, is most often the case. To determine whether

Swedish Council on Technology Assessement2005

1845. Oestrogen plus progestogen increased risk of breast cancer in postmenopausal wome

Oestrogen plus progestogen increased risk of breast cancer in postmenopausal wome Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women Article Text Treatment Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women Free Cathy R Kessenich , RN, DSN, ARNP Statistics from Altmetric.com No Altmetric data available

Evidence-Based Nursing (Requires free registration)2005

1846. Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths

Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths Article Text Treatment Review: limited evidence on regular breast examination does

Evidence-Based Nursing (Requires free registration)2005

1847. Follow-up after treatment for breast cancer

Follow-up after treatment for breast cancer guideline-9 Information for… Search for Keyword: Submit Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update) Clinical practice guidelines for the care and treatment of breast cancer: 9. Follow-up after treatment for breast cancer (2005 update) Eva Grunfeld, Sukhbinder Dhesy-Thind, Mark Levine, for the Steering Committee on Clinical Practice Guidelines (...) for the Care and Treatment of Breast Cancer* Dr. Grunfeld is Professor of Medicine, Dalhousie University, and Director of Health Services and Outcomes Research, Cancer Care Nova Scotia, Halifax, NS. Dr. Dhesy-Thind is with the Cancer Care Ontario Juravinski Regional Cancer Centre and is Assistant Professor in the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Levine is Professor in the Departments of Clinical Epidemiology and Biostatistics and of Medicine and is the Buffet Taylor Chair

CMA Infobase (Canada)2005

1849. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. 15900007 2005 05 18 2005 05 23 2016 10 17 1538-3598 293 19 2005 May 18 JAMA JAMA Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. 2367-71 Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity. To describe adverse events associated with adjuvant chemotherapy for breast (...) cancer, which led to premature termination of a clinical trial. We conducted a prospective randomized multicenter study (Reposant sur des Arguments Pronostiques et Predictifs [RAPP]-01) to compare the effectiveness of 2 chemotherapy regimens. Patients (women aged 18-70 years) had primary unilateral breast cancer and either a moderate number of positive axillary lymph nodes (< or =3) or no positive axillary lymph nodes (N0), but were at a high risk of relapse. Patients were treated at 11 French cancer

JAMA2005

1850. Adjuvant docetaxel for node-positive breast cancer.

Adjuvant docetaxel for node-positive breast cancer. 15930421 2005 06 02 2005 06 07 2013 11 21 1533-4406 352 22 2005 Jun 02 The New England journal of medicine N. Engl. J. Med. Adjuvant docetaxel for node-positive breast cancer. 2302-13 We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. We randomly assigned 1491 women with axillary node-positive breast (...) as a result of infection. Two patients in each group died during treatment. Congestive heart failure and acute myeloid leukemia occurred in less than 2 percent of the patients in each group. Quality-of-life scores decreased during chemotherapy but returned to baseline levels after treatment. Adjuvant chemotherapy with TAC, as compared with FAC, significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer. Copyright 2005 Massachusetts Medical

NEJM2005

1851. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. 16236737 2005 10 20 2005 10 28 2015 11 19 1533-4406 353 16 2005 Oct 20 The New England journal of medicine N. Engl. J. Med. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. 1659-72 Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer (...) and completion of chemotherapy. This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observation in patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy. Data were available for 1694 women randomly assigned to two years of treatment with trastuzumab, 1694 women assigned to one year of trastuzumab, and 1693

NEJM2005

1852. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. 16236738 2005 10 20 2005 10 28 2015 11 19 1533-4406 353 16 2005 Oct 20 The New England journal of medicine N. Engl. J. Med. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. 1673-84 We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer. The National Surgical (...) Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) with the same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel (group 2). The North Central Cancer Treatment Group trial N9831 compared three regimens: doxorubicin and cyclophosphamide followed by weekly paclitaxel (group A), the same regimen followed by 52 weeks of trastuzumab after paclitaxel (group B), and the same regimen plus 52 weeks

NEJM2005

1853. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. 16325695 2005 12 05 2005 12 22 2015 06 16 1474-547X 366 9501 2005 Dec 03 Lancet (London, England) Lancet Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant (...) treatment of high-risk breast cancer: results of a multicentre phase III trial. 1935-44 Breast cancer with extensive axillary-lymph-node involvement has a poor prognosis after conventional treatment. In trials with historical controls, high-dose chemotherapy produced improved outcomes. We compared an intensive double-cycle high-dose chemotherapy regimen with an accelerated conventionally dosed regimen in high-risk breast cancer in a multicentre trial. Patients with at least nine positive nodes were

Lancet2005

1854. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. 16382061 2005 12 29 2006 01 05 2014 11 20 1533-4406 353 26 2005 Dec 29 The New England journal of medicine N. Engl. J. Med. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. 2747-57 The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen. We compared letrozole (...) with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women. The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant endocrine therapy regimens in postmenopausal women with hormone-receptor-positive breast cancer: letrozole, letrozole followed by tamoxifen, tamoxifen, and tamoxifen followed by letrozole. This analysis compares the two groups assigned to receive

NEJM2005

1855. Endoscopic axillary lymph node retrieval for breast cancer (IPG147)

Endoscopic axillary lymph node retrieval for breast cancer (IPG147) Endoscopic axillary lymph node retrieval for breast cancer | Guidance and guidelines | NICE Endoscopic axillary lymph node retrieval for breast cancer Interventional procedures guidance [IPG147] Published date: December 2005 Share Save Guidance T85.2 Block dissection of axillary lymph nodes Y76.3 Endoscopic approach to other body cavity or T86.2 Sampling of axillary lymph nodes Y76.3 Endoscopic approach to other body cavity (...) or T87.3 Excision or biopsy of axillary lymph node Includes: Excision or biopsy of supraclavicular lymph node NEC Y76.3 Endoscopic approach to other body cavity In addition an ICD-10 code from category C50.- Malignant neoplasm of breast or C79.8 Secondary malignant neoplasm of other specified sites is assigned. Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals

National Institute for Health and Clinical Excellence - Interventional Procedures2005

1856. Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women

Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women Article Text Therapeutics Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women Free Holly L Thacker , MD Statistics from Altmetric.com No Altmetric data available for this article. ( 2003 ) JAMA 289 , 3243 . Chlebowski RT

Evidence-Based Medicine (Requires free registration)2004

1857. Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths

Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths Article Text Therapeutics Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast

Evidence-Based Medicine (Requires free registration)2004

1858. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study.

Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. BACKGROUND: Survivors of childhood cancer are at risk for secondary breast cancer. Other than previous chest radiation therapy, risk factors for secondary breast cancer have not been established. OBJECTIVE: To identify risk factors for breast cancer among female survivors of childhood cancer. DESIGN: Retrospective cohort study. SETTING: The Childhood Cancer Survivor Study (CCSS), a multicenter study (...) of persons who survived more than 5 years after childhood cancer diagnosed from 1970 to 1986. PARTICIPANTS: Among 6068 women in the CCSS, 95 women had 111 confirmed cases of breast cancer. MEASUREMENTS: Standardized incidence ratios for breast cancer were calculated by using age-specific incidence rates in the general population. Breast cancer incidence was evaluated with respect to primary cancer diagnosis and therapy, age at and time since primary diagnosis, menstrual and reproductive history

Annals of Internal Medicine2004

1859. Prophylactic mastectomy for the prevention of breast cancer.

Prophylactic mastectomy for the prevention of breast cancer. BACKGROUND: Breast cancer is the most common cancer and the second most common cause of cancer-related death among North American and Western European women. Recent progress in understanding the genetic basis of breast cancer, along with rising incidence rates, have resulted in increased interest in prophylactic mastectomy as a method of preventing breast cancer, particularly in those with familial susceptibility. OBJECTIVES (...) : The primary objective was to determine whether prophylactic mastectomy reduces death from any cause in women who have never had breast cancer and in women who have a history of breast cancer in one breast. The secondary objective was to examine the effect of prophylactic mastectomy on other endpoints including breast cancer incidence, breast cancer mortality, disease-free survival, physical morbidity, and psychosocial outcomes. SEARCH STRATEGY: Electronic searches were performed in the Cochrane Central

Cochrane2004

1860. Growth patterns and the risk of breast cancer in women.

Growth patterns and the risk of breast cancer in women. BACKGROUND: Adult height and body-mass index influence the risk of breast cancer in women. Whether these associations reflect growth patterns of the fetus or growth during childhood and adolescence is unknown. METHODS: We investigated the association between growth during childhood and the risk of breast cancer in a cohort of 117,415 Danish women. Birth weight, age at menarche, and annual measurements of height and weight were obtained (...) from school health records. We used the data to model individual growth curves. Information on vital status, age at first childbirth, parity, and diagnosis of breast cancer was obtained through linkages to national registries. RESULTS: During 3,333,359 person-years of follow-up, 3340 cases of breast cancer were diagnosed. High birth weight, high stature at 14 years of age, low body-mass index (BMI) at 14 years of age, and peak growth at an early age were independent risk factors for breast cancer

NEJM2004